By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


SEARCH JOBS

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.

YEAR FOUNDED:

1840

LEADERSHIP:

Founder: Emil Mallinckrodt

CEO: Mark Trudeau

CFO: Matthew Harbaugh

JOBS:

Please click here for Mallinckrodt job opportunities.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Mallinckrodt
Employees:
Symbol: MNK
 



Industry
Medical Device


Collaborations

Advanced Magnetics, Inc.  GastroMARK in North America





Company News
Mallinckrodt (MNK) And Massachusetts Health & Hospital Association Announce Joint Initiative For Developing Pain Stewardship Programs Within Hospitals 6/21/2017 10:36:07 AM
Mallinckrodt (MNK) Enrolls First Patient In Phase IIB Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS) 6/15/2017 6:42:30 AM
Mallinckrodt (MNK) Enrolls First Patient In Phase III Trial Of StrataGraft Regenerative Skin Tissue 6/7/2017 6:34:48 AM
Intellipharmaceutics (IPCI) Announces Launch Of Generic Seroquel XR By Mallinckrodt (MNK) 6/6/2017 7:25:40 AM
Mallinckrodt (MNK) Exploring Sale Of $2 Billion Generics Biz 5/31/2017 6:28:29 AM
Mallinckrodt (MNK) Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse 5/26/2017 6:20:13 AM
First Patient Enrolled In Mallinckrodt (MNK) Phase IV Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse 5/24/2017 7:02:27 AM
Mallinckrodt (MNK) Reports Earnings Results For First Quarter Of Fiscal 2017 5/8/2017 10:01:56 AM
First Patient Enrolled In Mallinckrodt (MNK) Phase II Trial Of StrataGraft Regenerative Skin Tissue 5/5/2017 6:45:24 AM
Mallinckrodt (MNK) Data From New Company-Sponsored Studies Presented At American Academy of Neurology 69th Annual Meeting 4/28/2017 7:03:48 AM
12345678910...
//-->